High-flow nasal cannula manufacturers are leveraging the acute shortage of ventilators during the coronavirus pandemic, with an effective low-cost treatment alternative. ROCKVILLE, MD / ACCESSWIRE / ...

Austin, TX, USA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “High Flow Nasal Cannula Market Size, Trends and Insights By Product Type (Single ...

Study finds that high-flow nasal oxygen therapy is as effective as traditional noninvasive ventilation and a better alternative (1 Trusted Source High-Flow Nasal Oxygen vs Noninvasive Ventilation in ...

The global high flow nasal cannula Industry has witnessed substantial growth in recent years, driven by a combination of technological advancements, increased prevalence of respiratory disorders, and ...

Jaipur: High flow nasal cannula (HFNC), a type of oxygen therapy which is normally given to patients with pneumonia, heart failure and sleep apnea, is proving beneficial for Covid patients who are ...

Please provide your email address to receive an email when new articles are posted on . Researchers assessed high-flow nasal therapy in two sequences. The changes in dyspnea and respiratory drive with ...

Market research company Future Market Insights’ projections on the High Flow Nasal Cannula Market reveal that the market is slated to be valued at ~US$ 18 Bn by 2030. Technological advancements by key ...

High-flow nasal cannula (HFNC) oxygen therapy is a relatively recent innovation in adult critical care units. It delivers warm humidified oxygen at high flow rates (between 15 and 60 L/min) through a ...

The complexity of the disease has made ventilator use challenging. Treatment of COVID-19 has been a medical puzzle for front-line doctors largely learning about the disease in real-time without proven ...

Compared to ventilator care, nasal high flow therapy for seriously ill coronavirus patients has several benefits, including the ability to mobilize patients. Nasal high flow (NHF) therapy is a less ...

Are (population) preterm infants (≥28 to <37 weeks), who are treated with (intervention) heated, humidified, high-flow nasal cannulae (HHHFNC) at (Outcomes) increased risk of treatment failure of ...